CASE STUDY: AstraZeneca
Liverpool has a major concentration of bio-manufacturing with global players developing next generation pharmaceutical products. Multinational pharmaceutical and biopharmaceutical company, AstraZeneca is an example of the commitment to invest in bio-manufacturing in the region.
Around 360 people work at AstraZeneca’s biologics site in Liverpool, which has unique facilities to bulk-manufacture the nasal spray influenza vaccine and can produce up to 19 million vaccine doses every year. Since 2010, there has been £75 million of investment at the site to support increased production of the vaccine for use in the UK and internationally.
AstraZeneca supplies the nasal spray vaccine as an important part of the Government’s extended childhood flu vaccination programme.
Over time, as the programme rolls out, all children between the ages of two and 17 will be vaccinated against flu each year. The spray is solely produced by AstraZeneca and 100 per cent of the medication is manufactured in Liverpool.
AstraZeneca is an active partner with local universities and research bodies. The Centre for Drug Safety Science at the University of Liverpool, brings together companies like AstraZeneca with regulatory authorities and academic researchers to work collaboratively on drug safety.
Liverpool City Region works to help AstraZeneca push the boundaries of science to deliver life-changing medicines across the world.